Roswell Park Cancer Institute, University at Buffalo, Buffalo, NY 14263, USA.
Cancer J. 2010 Nov-Dec;16(6):606-13. doi: 10.1097/PPO.0b013e318201fdac.
Continued research is critical to build upon past improvements in mortality and morbidity from cancer. Provisions in the Patient Protection and Affordable Care Act (PPACA) of 2010 address health research that affect cancer research in many positive and some potentially negative ways. The impact of PPACA on cancer research must be viewed in the context of the federal economic situation and the ongoing reform of the American clinical trial system. Major components of PPACA affect cancer research including requiring insurance coverage of standard care provided as part of clinical trials, establishment and funding of the Patient Centered Outcomes Research Institute focused on comparative effectiveness research, and establishment of the Cures Acceleration Network to foster rapid translation of basic research to the bedside. This article reviews these programs, their strengths, and our concerns regardingtheir potential shortfalls and areas needed to support cancer research on which PPACA is silent.
继续研究对于建立在过去癌症死亡率和发病率改善的基础上至关重要。2010 年《患者保护与平价医疗法案》（PPACA）中的规定以积极和一些潜在负面的方式影响着癌症研究。必须从联邦经济状况和美国临床试验系统持续改革的角度来看待 PPACA 对癌症研究的影响。PPACA 的主要组成部分影响着癌症研究，包括要求保险覆盖作为临床试验一部分提供的标准护理、建立和资助以比较疗效研究为重点的患者为中心的结果研究所，以及建立治疗加速网络以促进将基础研究迅速转化为床边治疗。本文综述了这些项目及其优势，以及我们对它们可能存在的不足和需要支持的领域的关注，而这些领域在 PPACA 中没有涉及。
